TH
BMRN icon

Timber Hill’s BioMarin Pharmaceuticals BMRN Stock Holding History

Timber Hill’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,600
Closed -$856K – 327
2017
Q4 		$856K Sell
9,600
-8,900
-48% -$774K 0.06% 313
2017
Q3 		$1.72M Sell
18,500
-9,300
-33% -$822K 0.16% 110
2017
Q2 		$2.52M Sell
27,800
-200
-0.7% -$18.2K 0.1% 172
2017
Q1 		$2.46M Sell
28,000
-17,600
-39% -$1.57M 0.02% 616
2016
Q4 		$3.78M Buy
45,600
+3,700
+9% +$318K 0.02% 627
2016
Q3 		$3.88M Sell
41,900
-21,700
-34% -$2.04M 0.02% 556
2016
Q2 		$4.95M Buy
63,600
+25,100
+65% +$2.13M 0.02% 537
2016
Q1 		$3.17M Sell
38,500
-4,800
-11% -$391K 0.02% 705
2015
Q4 		$4.54M Buy
43,300
+18,600
+75% +$1.94M 0.02% 582
2015
Q3 		$2.6M Buy
24,700
+15,100
+157% +$2.02M 0.01% 870
2015
Q2 		$1.31M Sell
9,600
-45,600
-83% -$5.65M 0.01% 1346
2015
Q1 		$6.88M Buy
55,200
+40,300
+270% +$4.27M 0.03% 452
2014
Q4 		$1.35M Sell
14,900
-30,400
-67% -$2.53M 0.01% 1262
2014
Q3 		$3.27M Sell
45,300
-18,100
-29% -$1.19M 0.01% 833
2014
Q2 		$3.94M Buy
63,400
+4,800
+8% +$290K 0.02% 736
2014
Q1 		$4M Buy
58,600
+45,000
+331% +$3.32M 0.02% 745
2013
Q4 		$957K Sell
13,600
-4,800
-26% -$326K ﹤0.01% 1865
2013
Q3 		$1.33M Sell
18,400
-37,900
-67% -$2.52M ﹤0.01% 1751
2013
Q2 		$3.14M Buy
+56,300
New +$3.51M 0.01% 1117

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Timber Hill's BMRN Position: Q4 2017 in Review

Timber Hill sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 7,606 shares — an estimated $661K sold.

Timber Hill first reported a position in BMRN in Q2 2013 and held it in 12 quarters. The position peaked at $1.39M in Q3 2016. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Timber Hill reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Timber Hill sold 7,606 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $661K.
  • Timber Hill first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Timber Hill's BioMarin Pharmaceuticals position peaked at $1.39M in Q3 2016.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Timber Hill's 13F filing for Q4 2017, filed 9 Feb 2018.